

Juan JosÃ© Lahuerta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4020816/publications.pdf>

Version: 2024-02-01

135
papers

14,533
citations

57631

44
h-index

19690

117
g-index

136
all docs

136
docs citations

136
times ranked

9513
citing authors

#	ARTICLE	IF	CITATIONS
1	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	2.5	19
2	The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. <i>Biomarker Research</i> , 2022, 10, 1.	2.8	22
3	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2598-2609.	3.2	14
4	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3234-3239.	2.5	18
5	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	2.0	13
6	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	2.8	8
7	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. <i>Blood Cancer Journal</i> , 2022, 12, 76.	2.8	5
8	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	0.8	115
9	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	0.8	40
10	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. <i>Leukemia</i> , 2021, 35, 245-249.	3.3	10
11	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1â€œcid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. <i>British Journal of Haematology</i> , 2021, 192, 522-530.	1.2	8
12	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021, 137, 49-60.	0.6	80
13	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. <i>Blood Advances</i> , 2021, 5, 1340-1343.	2.5	7
14	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	2.8	14
15	Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 413-420.	0.2	6
16	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 801-812.	5.1	162
17	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.	0.6	11
18	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	0.6	23

#	ARTICLE	IF	CITATIONS
19	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	1.7	11
20	The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. <i>Diagnostics</i> , 2021, 11, 2020.	1.3	4
21	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021, 138, 76-76.	0.6	7
22	Assessment of Treatment Response By Iife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial. <i>Blood</i> , 2021, 138, 544-544.	0.6	7
23	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 1596-1596.	0.6	0
24	Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial. <i>Blood</i> , 2021, 138, 466-466.	0.6	19
25	Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics. <i>Frontiers in Oncology</i> , 2021, 11, 800309.	1.3	1
26	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	0.8	175
27	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.	2.8	60
28	Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. <i>Blood Cancer Journal</i> , 2020, 10, 103.	2.8	57
29	The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. <i>PLoS ONE</i> , 2020, 15, e0237155.	1.1	21
30	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 6023-6033.	2.5	15
31	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.	1.7	7
32	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	3.3	26
33	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	0.6	76
34	Measurable residual disease in multiple myeloma: ready for clinical practice?. <i>Journal of Hematology and Oncology</i> , 2020, 13, 82.	6.9	24
35	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 14.	2.8	16
36	Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance. <i>Blood</i> , 2020, 136, 5-6.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	0.6	24
38	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2163-2171.	2.5	21
39	Title is missing!. , 2020, 15, e0237155.		0
40	Title is missing!. , 2020, 15, e0237155.		0
41	Title is missing!. , 2020, 15, e0237155.		0
42	Title is missing!. , 2020, 15, e0237155.		0
43	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i> , 2019, 134, 1337-1345.	0.6	148
44	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , The, 2019, 20, e302-e312.	5.1	290
45	Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 853-861.	2.0	33
46	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	0.6	11
47	Timing treatment for smoldering myeloma: is earlier better?. <i>Expert Review of Hematology</i> , 2019, 12, 345-354.	1.0	5
48	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	3.3	20
49	Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets. <i>Blood</i> , 2019, 134, 4355-4355.	0.6	2
50	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2019, 134, 781-781.	0.6	38
51	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.	0.6	14
52	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.	3.3	8
53	Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. <i>Bone Marrow Transplantation</i> , 2018, 53, 780-783.	1.3	6
54	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. <i>Haematologica</i> , 2018, 103, 880-889.	1.7	12

#	ARTICLE	IF	CITATIONS
55	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma â€” an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018, 8, 123.	2.8	81
56	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. <i>PLoS ONE</i> , 2018, 13, e0203392.	1.1	18
57	A predictive model for risk of early gradeâ€” infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	3.3	53
58	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	1.7	13
59	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
60	Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. <i>Hematological Oncology</i> , 2018, 36, 765-772.	0.8	15
61	VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2018, 132, 126-126.	0.6	13
62	Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2018, 132, 2142-2142.	0.6	7
63	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	0.6	41
64	Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. <i>Blood</i> , 2018, 132, 112-112.	0.6	3
65	Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 3170-3170.	0.6	0
66	Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1631-1640.	2.0	32
67	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	0.8	248
68	Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. <i>European Journal of Haematology</i> , 2016, 96, 532-540.	1.1	2
69	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016, 127, 1896-1906.	0.6	81
70	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. <i>Blood</i> , 2016, 127, 420-425.	0.6	51
71	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.	0.6	68
72	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	0.6	129

#	ARTICLE	IF	CITATIONS
73	Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. <i>Oncolmunology</i> , 2016, 5, e1250051.	2.1	71
74	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. <i>Blood</i> , 2016, 127, 3035-3039.	0.6	34
75	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3283-3283.	0.6	2
76	Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis. <i>Blood</i> , 2016, 128, 3308-3308.	0.6	2
77	Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. <i>Blood</i> , 2016, 128, 4503-4503.	0.6	2
78	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma. <i>Blood</i> , 2016, 128, 4505-4505.	0.6	4
79	The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators. <i>Blood</i> , 2016, 128, 5688-5688.	0.6	1
80	Incidence and Prognostic Impact of Secondary Neoplasia after High Dose Therapy Supported By Autologous Stem Cell Transplantation in Follicular Lymphoma. a Long Term Follow-up Analysis from the Geltamo Registry. <i>Blood</i> , 2016, 128, 3451-3451.	0.6	0
81	Functional and Pain Score Improvement with Vertebroplasty in De Novo Multiple Myeloma in a Public Institution in Mexico. <i>Blood</i> , 2016, 128, 3324-3324.	0.6	0
82	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	0.6	0
83	Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 2078-2078.	0.6	0
84	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. <i>Blood</i> , 2016, 128, 375-375.	0.6	1
85	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. <i>Leukemia Research Reports</i> , 2015, 4, 64-69.	0.2	12
86	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	2.8	48
87	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
88	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. <i>Blood</i> , 2015, 126, 858-862.	0.6	50
89	Bortezomib-based induction therapy followed by intravenous busulfan+melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 415-419.	0.6	8
90	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. <i>Blood</i> , 2015, 126, 2962-2962.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201.	0.6	3
92	Autologous Activated and Expanded Natural Killer Cells Are Safe and Clinically Actives in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1856-1856.	0.6	0
93	Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Disease Quantification and Risk Stratification in Multiple Myeloma. <i>Blood</i> , 2015, 126, 2972-2972.	0.6	0
94	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
95	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.	0.6	380
96	GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. <i>Blood</i> , 2014, 124, 1887-1893.	0.6	95
97	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	1.7	42
98	Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 178-178.	0.6	6
99	Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 3390-3390.	0.6	4
100	Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2014, 124, 3457-3457.	0.6	2
101	Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. <i>Blood</i> , 2014, 124, 3465-3465.	0.6	6
102	Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM. <i>Blood</i> , 2014, 124, 4776-4776.	0.6	1
103	Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma. <i>Blood</i> , 2014, 124, 3467-3467.	0.6	0
104	Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CYCLO-LEN-DEX) for Previously Untreated Patients with Light-Chain Amyloidosis (AL). <i>Blood</i> , 2014, 124, 2135-2135.	0.6	0
105	Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance. <i>Blood</i> , 2014, 124, 25-25.	0.6	2
106	High Dose Therapy with Autologous Stem Cell Transplantation (HDT/ASCT) Support in Follicular Lymphoma (FL) a Very Long Follow-up Analysis of 640 Patients of Geltamo Spanish Group Suggests That FL Might be Cured, Even in High-Risk Patients. <i>Blood</i> , 2014, 124, 675-675.	0.6	1
107	Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011). <i>Blood</i> , 2014, 124, 3980-3980.	0.6	0
108	Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. <i>Blood</i> , 2014, 124, 2108-2108.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. <i>New England Journal of Medicine</i> , 2013, 369, 438-447.	13.9	449
110	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 69-74.	2.0	60
111	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013, 98, 79-86.	1.7	132
112	Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 2155-2155.	0.6	3
113	Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 401-401.	0.6	6
114	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.	0.6	56
115	Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 3188-3188.	0.6	1
116	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	0.6	274
117	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	0.6	429
118	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1627-1633.	0.8	202
119	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	0.6	183
120	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011, 118, 4547-4553.	0.6	53
121	Impact of the Conditioning Regimen in Patients With Multiple Myeloma Who Undergo Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, e449-e449.	0.8	1
122	Busulfan 12 mg/kg plus melphalan 140 mg/m ² versus melphalan 200 mg/m ² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	1.7	101
123	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. <i>Lancet Oncology</i> , The. 2010, 11, 934-941.	5.1	427
124	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 216-222.	0.6	24
125	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. <i>Blood</i> , 2009, 114, 4369-4372.	0.6	67
126	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5775-5782.	0.8	263

#	ARTICLE	IF	CITATIONS
127	Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-PCR polymerase chain reaction: the prognostic impact of achieving molecular response. <i>British Journal of Haematology</i> , 2008, 142, 766-774.	1.2	52
128	A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , 2008, 112, 3591-3593.	0.6	247
129	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood</i> , 2008, 112, 4017-4023.	0.6	425
130	Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1448-1454.	2.0	83
131	Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. <i>Haematologica</i> , 2006, 91, 621-7.	1.7	39
132	International Staging System for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3412-3420.	0.8	2,404
133	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005, 90, 1365-72.	1.7	135
134	Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 67-75.	0.6	45
135	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. <i>British Journal of Haematology</i> , 2000, 109, 138-147.	1.2	69